Showing results (1-10 of 357) with videos related to
Sort By:
Pageof 36
Pharmacological Reviews|May 23, 2006
Multidrug resistance-associated proteins: expression and function in the central nervous systemShannon Dallas, David S Miller, Reina BendayanThe Journal of Pharmacology and Experimental Therapeutics|February 6, 2004
Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl)adenine by microgliaShannon Dallas, Lyanne Schlichter, Reina BendayanPharmaceutical Research|June 8, 2004
Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell linesPatrick T Ronaldson, Gloria Lee, Shannon Dallas, et al.Neuroreport|May 7, 2004
Multidrug resistance protein 1-mediated transport of saquinavir by microgliaShannon Dallas, Patrick T Ronaldson, Moise Bendayan, et al.The Journal of Pharmacology and Experimental Therapeutics|August 2, 2003
Functional expression of the multidrug resistance protein 1 in microgliaShannon Dallas, Xiaoping Zhu, Sylvain Baruchel, et al.Journal of Neuroinflammation|May 7, 2013
Microglial activation decreases retention of the protease inhibitor saquinavir: implications for HIV treatmentShannon Dallas, Michelle L Block, Deborah M Thompson, et al.Journal of Neurochemistry|October 15, 2015
In vivo and ex vivo regulation of breast cancer resistant protein (Bcrp) by peroxisome proliferator-activated receptor alpha (Pparα) at the blood-brain barrierMd Tozammel Hoque, Arpit Shah, Vijay More, et al.Pharmaceutical Research|September 14, 2004
Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disordersGloria Lee, Reina BendayanJournal of Neurochemistry|May 20, 2008
HIV-1 viral envelope glycoprotein gp120 produces oxidative stress and regulates the functional expression of multidrug resistance protein-1 (Mrp1) in glial cellsPatrick T Ronaldson, Reina BendayanTrends in Pharmacological Sciences|November 14, 2022
Pharmacokinetic considerations to optimize clinical outcomes for COVID-19 drugsChukwunonso K Nwabufo, Reina BendayanPageof 36